RO4905417

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Coronary Heart Disease, Graft Occlusion, VascularMyocardial InfarctionPeripheral Arterial Disease (PAD)

Phase 1

A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).

CompletedNCT00760565

Hoffmann-La RochePeripheral Arterial Disease (PAD)

Start: 2008-09-30End: 2011-06-30Updated: 2016-11-02

Phase 2

A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

CompletedNCT01245634

Hoffmann-La RocheCoronary Heart Disease, Graft Occlusion, Vascular

Start: 2010-12-31End: 2013-05-31Updated: 2016-11-02

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

CompletedNCT01327183

Hoffmann-La RocheMyocardial Infarction

Start: 2011-05-31End: 2012-10-31Updated: 2016-11-02

Related Papers

Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial

Journal of the American Heart Association2016-10-2675 citations

Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial.

2013-03-10157 citations